Highlights BioVie Inc.

Equities

BIVI

US09074F2074

Delayed Nasdaq Other stock markets 01:19:51 2024-04-30 pm EDT			5-day change	1st Jan Change
0.491 ^USD	-0.81%		+1.63%	-60.33%

Apr. 29	BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID	MT
Apr. 29	BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim for the Treatment of Long COVID	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID	Apr. 29	MT
BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim for the Treatment of Long COVID	Apr. 29	CI
BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities	Mar. 11	CI
BioVie Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
BioVie Says Modified Phase 3 Trial for Alzheimer's Disease Treatment Missed Statistical Significance Amid Protocol Errors	Nov. 29	MT
BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer?s Disease	Nov. 29	CI
BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease - The Liver Meeting® 2023	Nov. 13	CI
BioVie Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 08	CI
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023	23-10-26	CI
BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson?s Disease and Movement Disorders	23-08-28	CI
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-16	CI
Biovie Inc. Announces Phase 3 Trial of Ne3107 in Alzheimer's Disease	23-07-18	CI
BioVie Inc. to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease	23-07-10	CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
BioVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-12	CI
BioVie Inc. Announces the Pausing of Patient Enrollment in Ascites Phase 2B Trial, Encouraging Efficacy Data Is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial	23-03-13	CI
BioVie Inc. Announces Additional Findings from Phase 2 Parkinson's Disease Trial	23-03-06	CI
BioVie Inc. Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease	23-03-02	CI
BioVie Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-10	CI
Biovie Inc. Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: Ne3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia	22-12-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioVie Inc.

Equities

BIVI

US09074F2074

Highlights

Filters